盐酸雷洛昔芬治疗绝经后妇女骨质疏松临床研究  

The clinical study of raloxifene in the treatment of postmenopausal osteoporosis

作　　者：王亮[1] 马远征[1] 张妍[1] 陈立英[1] 白颖[1] 陈琼[1] 陈烨[2] 马伟凤[1] 杨帆[1] 谢媛媛[1] 马彦巧 胡江伟[1] 杨国花[1] 王文娇[1] 

机构地区：[1]解放军第309医院全军骨科中心骨内科,北京100091 [2]第二炮兵指挥学院门诊部,湖北武汉430012

出　　处：《中国骨质疏松杂志》2014年第7期824-826,共3页Chinese Journal of Osteoporosis

基　　金：全军十二五课题基金项目(CWS11J169)

摘　　要：目的研究盐酸雷洛昔芬(Raloxifene HCL,RLX)治疗绝经后骨质疏松妇女临床疗效,骨密度、血生化指标及血脂的影响。方法选择2010年1月-2013年1月在我科住院绝经后骨质疏松患者共90例,每人每天服用元素钙600 mg,活性维生素D 0.5μg作为基本补充剂,每日服用盐酸雷洛昔芬60 mg,共治疗12个月。观察指标为:腰椎、髋部骨密度;骨标志物、血生化指标。骨密度测定采用双能X线吸收法,骨标志物测定采用酶联免疫吸附法,血生化检测应用酶法。结果研究结束时,腰椎骨密度0.848±0.167,Ward三角骨密度0.536±0.126,较治疗前0.842±0.181、0.500±0.112均有显著提高,差异具有统计学意义;治疗后,血清CTX、BGP均较治疗前显著降低,而PTH较治疗前升高;治疗前后两组血脂水平无显著差异。结论盐酸雷洛昔芬能够显著增加绝经后骨质疏松妇女腰椎和髋部的骨密度,显著降低骨转换率,对绝经后妇女骨质疏松治疗效果较好。Objective To investigate the effect of raloxifene HCL （RLX） on serum biochemistry, bone markers, and bone mineral density （BMD） in women with postmenopausal osteoporosis. Methods A total of 90 patients with postmenopausal osteoporosis, who were hospitalized in our department from January 2010 to January 2010, were selected. All the patients took 600 mg calcium and 0.5 p,g active vitamin D every day as the basic supplements. The patients also took 60 mg RLX every week for 12 months. The obvervational indexes included BMD of the lumbar vertebrae and the hip, bone markers, and serum biochemical indexes. BMD was detected using dual-energy X-ray absorptiometry. Bone markers were determined using enzyme-linked immunosorbent method. Serum biochemical indexes were detected using enzymic method. Results BMD of the lumbar vertebrae and the Ward＇ s triangle was 0. 848 ± 0. 167 and 0. 536 ±0. 126, respectively, which was higher than that before the treatment （0. 842 ± 0.181 and 0. 500± 0.112, respectively） , and the difference was statistically significant （P 〈 0.05 ）. The serum levels of CTX and BGP decreased significantly than those before the treatment, while the serum PTH level was higher than that before the treatment. No significant difference of the serum levels of blood lipids between two groups was observed. Conclusion Raloxifene hydrochloride increases BMD of the lumbar vertebrae and the hip in women with postmenopausal osteoporosis, and reduces the bone turnover significantly. So, it has good therapeutic effect for postmenopausal osteoporosis.

关 键 词：雷洛昔芬 骨密度 代谢 骨质疏松 绝经后妇女 

分 类 号：R914.5[医药卫生—药物化学] R589[医药卫生—药学]